Additional Treatments Offer Little Benefit for Pancreatic Cancer: Study

TUESDAY, May 3, 2016 — Additional treatments for locally advanced pancreatic cancer don’t appear to boost survival, a new French study reports.
Researchers looked at the effects of adding a second drug — erlotinib (Tarceva) — to the initial round…
Source: Topamax